Akums Secures European CEP Approval for Cefpodoxime Proxetil API

Akums Drugs and Pharmaceuticals has cleared a significant regulatory checkpoint: a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines and HealthCare (EDQM) for its Cefpodoxime Proxetil active pharmaceutical ingredient. For European finished-dose manufacturers sourcing this third-generation cephalosporin, the approval opens a qualified, auditable API supply route from an Indian CDMO operating under Ph. Eur. standards.

The CEP pathway requires demonstration that an API's manufacturing process and impurity profile conform to the relevant European Pharmacopoeia monograph, a standard that sits alongside ICH Q11 expectations for development and manufacture of drug substances. Achieving CEP status removes a substantial documentation burden for European marketing authorisation holders, who can reference the certificate directly in their dossiers rather than submitting a full Active Substance Master File review. That efficiency is a material consideration for QA directors managing supplier qualification timelines.

Cefpodoxime Proxetil is a prodrug ester with established demand across respiratory and urinary tract infection indications in European markets. Qualifying a second-source API supplier under CEP reduces single-source exposure for procurement teams and supports continuity-of-supply obligations that regulators increasingly scrutinise during inspections. For regulatory affairs leads at finished-dose sites, the Akums certificate is a ready reference document, provided their own site's quality agreement and supplier audit programme are current.

The approval also reflects a broader pattern among Indian API manufacturers: systematic pursuit of EDQM CEP and US FDA Drug Master File registrations to position their facilities as primary, not contingent, supply partners for regulated-market customers. Akums, which operates multiple GMP-certified manufacturing sites, has been extending its regulated-market API portfolio across several therapeutic categories. Each CEP adds a verifiable compliance credential that procurement and QA functions at European pharma companies can act on without initiating a full technical assessment from scratch.

The certificate's practical value will be tested against how quickly European buyers can complete their own supplier qualification steps, including on-site audits and quality agreement execution, before the API can enter commercial supply chains.

Source: Indian Pharma Post via Media4Growth, 2 June 2026.